CSL (OTCMKTS:CSLLY) Shares Gap Up – Time to Buy?

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped up prior to trading on Thursday . The stock had previously closed at $59.31, but opened at $62.1750. CSL shares last traded at $61.67, with a volume of 9,368 shares.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CSLLY. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. Canaccord Genuity Group upgraded CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Finally, Royal Bank Of Canada raised CSL from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.

CSL Stock Up 1.3%

The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average is $59.08 and its 200-day moving average is $67.70.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.